Canine Leptospirosis: Serovars, Clinical Features, and Vaccine Update

Introduction

Canine leptospirosis is a globally distributed zoonotic bacterial disease caused by pathogenic spirochetes of the genus Leptospira. The disease presents a significant diagnostic and therapeutic challenge in veterinary medicine due to its variable clinical manifestations, ranging from subclinical infection to fulminant hepatorenal failure. This article provides a detailed examination of the relevant serovars, the pathophysiology of acute kidney injury (AKI), diagnostic methodologies, and an evidence-based update on vaccination strategies, specifically comparing bivalent and quadrivalent formulations.

Etiology and Serovar Epidemiology

The genus Leptospira is classified into over 250 serovars, grouped into antigenically related serogroups. Pathogenic species, primarily Leptospira interrogans sensu lato, are responsible for clinical disease in dogs. The serovar is the fundamental taxonomic unit for epidemiological and vaccinological purposes, defined by the composition of lipopolysaccharide (LPS) antigens [1, 2].

Common Canine Serovars

The serovars most frequently associated with canine disease vary geographically but consistently include L. interrogans serovars Icterohaemorrhagiae and Canicola. Other clinically relevant serovars include Grippotyphosa, Pomona, Bratislava, and Australis [3, 4].

Table 1. Primary Canine Leptospira Serovars and Reservoir Hosts

L. interrogans serovar Icterohaemorrhagiae is classically associated with severe icteric disease and is maintained in rat populations. L. canicola is adapted to the canine host and historically caused a high proportion of cases before widespread vaccination reduced its prevalence [5]. However, recent epidemiological studies indicate a shift toward serovars not traditionally included in older bivalent vaccines, such as Grippotyphosa and Pomona, highlighting the need for broader serovar coverage [6, 7].

Molecular Basis of Serovar Specificity

The antigenic diversity of Leptospira serovars is determined by the structure of the LPS O-antigen. The genetic loci responsible for O-antigen biosynthesis contain a mosaic of genes subject to horizontal gene transfer and recombination, driving serovar diversity [8]. This genetic plasticity complicates vaccine development, as protective immunity is largely serovar-specific and mediated by antibodies against LPS [9].

Pathogenesis and Clinical Features

Mechanisms of Infection and Tissue Tropism

Leptospira spp. enter the host through mucous membranes or abraded skin. The spirochetes possess high motility conferred by periplasmic flagella, enabling rapid dissemination via the bloodstream during the leptospiremic phase [10]. The bacteria adhere to endothelial cells and penetrate tissues, establishing infection in the renal tubules, liver, and lungs.

The primary virulence factors include:

• Lipopolysaccharide (LPS): Endotoxic activity and resistance to complement-mediated killing [11].
• Leptospiral immunoglobulin-like (Lig) proteins: Surface-exposed proteins that bind extracellular matrix components such as fibronectin and laminin, facilitating adhesion [12].
• Hemolysins (e.g., Sph2, HlyX): Pore-forming toxins that cause cellular damage and hemolysis [13].
• Outer membrane proteins (OMPs) (e.g., LipL32, LipL41): Abundant lipoproteins involved in pathogenesis and host immune recognition [14].

Acute Kidney Injury: Pathophysiology

Renal pathology is a hallmark of leptospirosis. The spirochetes invade the renal interstitium and proximal tubular epithelial cells, leading to:

1. Tubular Necrosis: Direct cytotoxic damage from bacterial products and host inflammatory responses causes acute tubular necrosis (ATN). The proximal convoluted tubules are particularly vulnerable due to their high metabolic activity and role in solute reabsorption [15].
2. Interstitial Nephritis: A robust inflammatory infiltrate, predominantly of mononuclear cells (lymphocytes, plasma cells, macrophages), develops in the interstitium. This inflammation disrupts tubular function and renal blood flow [16].
3. Vasculitis and Ischemia: Leptospiral components induce endothelial damage and microvascular thrombosis, leading to reduced glomerular filtration rate (GFR) and renal ischemia [17].

The resulting AKI is characterized by azotemia, isosthenuria, and tubular proteinuria. In severe cases, oliguric or anuric renal failure ensues.

Clinical Syndromes

Clinical presentation is highly variable and depends on the infecting serovar, infectious dose, host immune status, and age. The disease is often categorized into peracute, acute, subacute, and chronic forms.

Table 2. Clinical Syndromes of Canine Leptospirosis

Hepatic Involvement: Icterus results from hepatocellular damage and cholestasis. Serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) are moderately elevated. Hyperbilirubinemia is a negative prognostic indicator [18].

Pulmonary Hemorrhage Syndrome: A severe manifestation characterized by pulmonary hemorrhage and acute respiratory distress. Pathophysiology involves diffuse alveolar damage and endothelial injury, leading to intra-alveolar hemorrhage. This syndrome carries a high mortality rate [19].

Coagulopathies: Thrombocytopenia is common, resulting from immune-mediated destruction and consumption. Disseminated intravascular coagulation (DIC) can occur in severe cases [20].

Diagnostic Approaches

Diagnosis of canine leptospirosis requires a combination of clinical suspicion, hematological and biochemical profiling, and specific laboratory testing.

Hematology and Serum Biochemistry

• Complete Blood Count (CBC): Thrombocytopenia is a consistent finding. Leukocytosis with a left shift is common in acute cases. Anemia may be present due to hemolysis or blood loss.
• Serum Biochemistry: Azotemia (elevated blood urea nitrogen and creatinine) indicates renal dysfunction. Elevated liver enzymes (ALT, ALP) and bilirubin suggest hepatic involvement. Electrolyte imbalances, particularly hyponatremia and hypokalemia, are frequently observed [21].
• Urinalysis: Isosthenuria (specific gravity 1.008-1.012) in a dehydrated patient is a key indicator of renal tubular damage. Proteinuria, hematuria, and pyuria are common. Active leptospiruria can be detected via dark-field microscopy, though this method has low sensitivity [22].

Serological Testing

Microscopic Agglutination Test (MAT): The MAT is the reference standard serological test. It detects agglutinating antibodies (primarily IgM) against a panel of live Leptospira serovars. A single titer of 1:800 or greater in a vaccinated dog with compatible clinical signs is considered supportive of active infection. A four-fold rise in titer between acute and convalescent (2-4 weeks later) samples is confirmatory [23]. Limitations include the need for a panel of live serovars, subjective interpretation, and inability to differentiate between vaccine-induced and infection-induced antibodies [24].

Enzyme-Linked Immunosorbent Assay (ELISA): Commercial ELISA kits detect anti-Leptospira IgM antibodies. These assays offer higher throughput and objectivity compared to MAT. However, they may have variable sensitivity and specificity depending on the antigen used. The detection of IgM is useful for diagnosing acute infection, as IgM levels rise rapidly in the first week of illness [25]. For a detailed discussion of ELISA principles, see the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Molecular Diagnostics

Polymerase Chain Reaction (PCR): PCR assays targeting conserved genes such as 16S rRNA, lipL32, or secY provide rapid and specific detection of pathogenic Leptospira DNA [26]. Real-time PCR (qPCR) offers quantification and is highly sensitive. PCR can detect leptospiral DNA in blood during the leptospiremic phase (first 4-7 days of illness) and in urine after the second week of infection [27]. PCR is particularly valuable for early diagnosis before seroconversion occurs.

Table 3. Diagnostic Test Selection by Disease Phase

Diagnostic Algorithm

The following Mermaid diagram outlines a clinical decision tree for diagnosing canine leptospirosis.

flowchart TD
    A[Clinical Suspicion: Fever, Vomiting, PU/PD, Icterus], > B{Thrombocytopenia?}
    B, Yes, > C[Azotemia or Isosthenuria?]
    B, No, > D[Consider other diagnoses]
    C, Yes, > E[Collect Blood and Urine]
    C, No, > F[Collect Blood and Urine for PCR]
    E, > G[Perform qPCR on Blood]
    G, Positive, > H[Diagnosis Confirmed: Acute Leptospiremia]
    G, Negative, > I[Perform IgM ELISA]
    I, Positive, > J[Probable Acute Infection]
    I, Negative, > K[Collect Convalescent Serum for MAT]
    F, > L[Perform qPCR on Urine]
    L, Positive, > M[Diagnosis Confirmed: Leptospiruria]
    L, Negative, > N[Perform MAT on Paired Sera]
    N, 4-fold rise, > O[Confirmatory Diagnosis]
    N, Negative, > P[Leptospirosis Unlikely]

Vaccine Update: Bivalent versus Quadrivalent

Vaccination is the cornerstone of leptospirosis prevention in dogs. The evolution of vaccine formulations reflects the changing epidemiological landscape of circulating serovars.

Historical Context

Early vaccines were bacterins containing whole inactivated L. canicola and L. icterohaemorrhagiae (bivalent). These vaccines effectively reduced the incidence of disease caused by these two serovars but offered no cross-protection against others [28]. The emergence of serovars Grippotyphosa and Pomona as significant causes of disease led to the development of quadrivalent vaccines.

Bivalent Vaccines

Bivalent vaccines contain antigens from serovars Canicola and Icterohaemorrhagiae. They are still used in some regions but are increasingly considered inadequate for comprehensive protection. Studies have shown that dogs vaccinated with bivalent products remain susceptible to infection and disease from serovars Grippotyphosa and Pomona [29, 30].

Quadrivalent Vaccines

Quadrivalent vaccines include antigens from serovars Canicola, Icterohaemorrhagiae, Grippotyphosa, and Pomona. These vaccines provide broader serovar coverage and are now recommended by most veterinary infectious disease guidelines [31].

Table 4. Comparison of Bivalent and Quadrivalent Leptospirosis Vaccines

Vaccine Immunology and Limitations

Leptospira vaccines are bacterins that induce a humoral immune response directed primarily against LPS. This response is serovar-specific. The inability to generate cross-protective immunity against heterologous serovars is a fundamental limitation of current bacterin technology [32].

Adverse Events: Vaccination against leptospirosis has historically been associated with a higher rate of adverse reactions compared to other canine vaccines. These reactions include type I hypersensitivity (urticaria, angioedema, anaphylaxis) and type III hypersensitivity (immune complex-mediated vasculitis) [33]. Modern quadrivalent vaccines, produced using refined purification processes, have demonstrated a safety profile comparable to bivalent products [34].

Duration of Immunity (DOI): The DOI for leptospirosis vaccines is generally accepted as 12 months. Annual revaccination is recommended for dogs at sustained risk of exposure [35]. Studies on DOI for quadrivalent vaccines have shown protective antibody titers persist for at least one year, though the correlation between antibody titer and protection is not absolute [36].

Vaccine Recommendations

The World Small Animal Veterinary Association (WSAVA) and American Animal Hospital Association (AAHA) guidelines recommend the use of quadrivalent leptospirosis vaccines for all dogs, regardless of lifestyle, in regions where the disease is endemic [37, 38]. The rationale is that even dogs with minimal outdoor exposure can encounter infected wildlife reservoirs (e.g., rodents, raccoons) in urban environments.

Vaccination Protocol:

1. Primary Course: Two doses administered 2-4 weeks apart, starting at 12 weeks of age.
2. Booster: One dose administered 12 months after the primary course.
3. Revaccination: Annually thereafter.

Treatment and Management

Therapeutic intervention for canine leptospirosis has two primary objectives: eliminating the infection and providing supportive care for organ dysfunction.

Antimicrobial Therapy

• Doxycycline: The drug of choice for treating leptospirosis. It is effective against both the acute bacteremic phase and the renal carrier state. The recommended dosage is 5 mg/kg orally every 12 hours for 14 days [39].
• Penicillins (e.g., Ampicillin, Penicillin G): Effective for clearing leptospiremia but do not eliminate the renal carrier state. They are often used parenterally in severely ill patients unable to tolerate oral medications [40].

Supportive Care

• Fluid Therapy: Aggressive intravenous fluid therapy with balanced crystalloid solutions is critical for managing AKI. Monitoring of urine output, central venous pressure, and body weight is essential to avoid fluid overload [41].
• Dialysis: In cases of oliguric or anuric renal failure unresponsive to medical management, hemodialysis or peritoneal dialysis may be required [42].
• Nutritional Support: Enteral nutrition via nasogastric tube is indicated for anorexic patients. Protein restriction is not recommended in AKI unless severe hyperphosphatemia is present [43].
• Antiemetics: Maropitant or ondansetron are used to control vomiting.

Prevention and Biosecurity

Prevention relies on vaccination, environmental management, and owner education.

• Rodent Control: Reducing exposure to rodent urine is critical. This includes sealing garbage, removing standing water, and controlling rodent populations on the property.
• Environmental Disinfection: Leptospira are susceptible to desiccation, heat, and common disinfectants (e.g., bleach solutions, quaternary ammonium compounds). Contaminated areas should be cleaned and disinfected [44].
• Owner Education: Owners must be informed of the zoonotic risk. Protective measures include wearing gloves when handling urine or cleaning contaminated areas, and practicing hand hygiene.

Conclusion

Canine leptospirosis remains a significant infectious disease with a complex epidemiology driven by multiple pathogenic serovars. The shift in predominant serovars from Canicola and Icterohaemorrhagiae to Grippotyphosa and Pomona has necessitated a change in vaccination strategy. Quadrivalent vaccines now represent the standard of care, providing broader serovar coverage. Accurate diagnosis requires a combination of PCR and serological testing, interpreted in the context of clinical signs and vaccination history. Early intervention with appropriate antimicrobials and aggressive supportive care is essential for improving patient outcomes.

References

[1] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. MediSci; 1999.

[2] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[3] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[4] Sykes JE, Hartmann K, Lunn KF, Moore GE, Stoddard RA, Goldstein RE. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[5] Prescott JF, McEwen B, Taylor J, Woods JP, Abrams-Ogg A, Wilcock B. Resurgence of leptospirosis in dogs in Ontario: recent findings. Can Vet J. 2002;43(12):955-961.

[6] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1996-2002. J Am Vet Med Assoc. 2004;225(1):72-77.

[7] Ghneim GS, Viers JH, Chomel BB, Kass PH, Descollonges DA, Johnson ML. Use of a case-control study and geographic information systems to determine environmental and demographic risk factors for canine leptospirosis. Vet Res. 2007;38(1):37-50.

[8] Bulach DM, Zuerner RL, Wilson P, et al. Genome reduction in Leptospira borgpetersenii reflects limited transmission potential. Proc Natl Acad Sci USA. 2006;103(39):14560-14565.

[9] Naiman BM, Alt D, Bolin CA, Zuerner R, Baldwin CL. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gamma delta T lymphocytes. Infect Immun. 2001;69(12):7550-7558.

[10] Charon NW, Goldstein SF. Genetics of motility and chemotaxis of a fascinating group of bacteria: the spirochetes. Annu Rev Genet. 2002;36:47-73.

[11] Que-Gewirth NL, Ribeiro AA, Kalb SR, et al. A methylated phosphate group and four amide-linked acyl chains in Leptospira interrogans lipid A. The membrane anchor of an unusual lipopolysaccharide. J Biol Chem. 2004;279(24):25420-25429.

[12] Matsunaga J, Barocchi MA, Croda J, et al. Pathogenic Leptospira species express surface-exposed proteins belonging to the bacterial immunoglobulin superfamily. Mol Microbiol. 2003;49(4):929-945.

[13] Lee SH, Kim KA, Park YG, Seong IW, Kim MJ, Lee YJ. Identification and partial characterization of a novel hemolysin from Leptospira interrogans serovar Lai. FEMS Microbiol Lett. 2000;187(1):91-95.

[14] Haake DA. Spirochaetal lipoproteins and pathogenesis. Microbiology. 2000;146(Pt 7):1491-1504.

[15] Faine S. Leptospirosis. In: Hausler WJ, Sussman M, eds. Topley and Wilson's Microbiology and Microbial Infections. 9th ed. Arnold; 1998:849-869.

[16] Arean VM. The pathologic anatomy and pathogenesis of fatal human leptospirosis (Weil's disease). Am J Pathol. 1962;40(4):393-423.

[17] De Brito T, Bohm GM, Yasuda PH. Vascular damage in acute experimental leptospirosis of the guinea pig. J Pathol. 1979;128(4):177-182.

[18] Greene CE, Sykes JE, Brown CA, Hartmann K. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-447.

[19] Klopfleisch R, Kohn B, Gruber AD. Pulmonary hemorrhage in canine leptospirosis: a comparative study of 12 cases. Vet Pathol. 2010;47(5):876-882.

[20] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome predictors of Leptospira interrogans Australis serogroup infection in dogs: a retrospective study of 20 cases (2001-2004). J Vet Intern Med. 2007;21(1):3-10.

[21] Rentko VT, Clark N, Ross LA, Schelling SH. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[22] Birnbaum N, Barr SC, Center SA, Schermerhorn T, Randolph JF, Simpson KW. Naturally acquired leptospirosis in 36 dogs: serological and clinicopathological features. J Small Anim Pract. 1998;39(5):231-236.

[23] Cole JR, Sulzer CR, Pursell AR. Improved microtechnique for the leptospiral microscopic agglutination test. Appl Microbiol. 1973;25(6):976-980.

[24] Hartmann K, Egberink H, Pennisi MG, et al. Leptospira species infection in cats: ABCD guidelines on prevention and management. J Feline Med Surg. 2013;15(7):576-581.

[25] Winzelberg S, Tasse SM, Goldstein RE, Chapman PS, Benedict A, Mason GD. Evaluation of a commercial enzyme-linked immunosorbent assay for the detection of antibodies against Leptospira spp. in dogs. J Am Vet Med Assoc. 2015;247(11):1270-1276.

[26] Stoddard RA, Gee JE, Wilkins PP, McCaustland K, Hoffmaster AR. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[27] Ahmed A, Engelberts MF, Boer KR, Ahmed N, Hartskeerl RA. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[28] Broughton ES, Scarnell J. Prevention of renal carriage of leptospirosis in dogs by vaccination. Vet Rec. 1985;117(12):307-311.

[29] Klaasen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Microbiol. 2003;95(1-2):121-132.

[30] Klaasen HL, van der Veen M, Sutton D, Molkenboer MJ. A new tetravalent canine leptospirosis vaccine provides at least 12 months immunity against infection. Vet Rec. 2014;174(4):94.

[31] Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227(7):1102-1108.

[32] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[33] Moore GE, HogenEsch H. Adverse vaccinal events in dogs and cats. Vet Clin North Am Small Anim Pract. 2010;40(3):393-407.

[34] Klaasen HL, van der Veen M, Sutton D, Molkenboer MJ. A new tetravalent canine leptospirosis vaccine provides at least 12 months immunity against infection. Vet Rec. 2014;174(4):94.

[35] Day MJ, Horzinek MC, Schultz RD, Squires RA. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2016;57(1):E1-E45.

[36] Klaasen HL, van der Veen M, Molkenboer MJ, Sutton D. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Microbiol. 2003;95(1-2):121-132.

[37] Day MJ, Horzinek MC, Schultz RD, Squires RA. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2016;57(1):E1-E45.

[38] Ford RB, Larson LJ, McClure KD, Schultz RD, Welborn LV. 2017 AAHA canine vaccination guidelines. J Am Anim Hosp Assoc. 2017;53(5):243-255.

[39] Greene CE, Sykes JE, Brown CA, Hartmann K. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-447.

[40] Alt DP, Zuerner RL, Bolin CA. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar hardjo. *